Medicago Inc MDCGF

PHASE 2 - Spectacular !

[kiskadog]

SO MUCH GOOD STUFF HERE.
i CERTAINLLY hope we all have the opportunity to continue to add shares until the next
results ( Part B ) .


QUEBEC CITY, Feb. 1, 2011 ( NewsWire via COMTEX News Network) --

- Company's results continue to be amongst the best for influenza vaccine manufacturing technologies - -Company's VLP induced the production of antibodies that cross react with multiple strains of influenza-

Medicago Inc. (TSX-V: MDG) a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today reported positive interim results from a Phase II human clinical trial with its H5N1 Avian Influenza VLP vaccine candidate ("H5N1 vaccine"). The vaccine was found to be safe, well tolerated and also induced a solid immune response.

"We believe our phase II interim study results continue to show impressive findings. These data demonstrate that our H5N1 vaccine is both safe and introduces cross-reactive antibody responses against multiple strains of H5N1," said Andy Sheldon, President and CEO of Medicago. "We also believe that our effective VLP vaccine, produced in less than one month, is capable of providing a rapid response to an influenza pandemic, a much needed solution. With these encouraging results in hand, we will proceed with part B of our Phase II study and look forward to reporting final data in Q2 2011."

"These results demonstrate that we have a safe product, as our H5N1 vaccine was well tolerated at all levels," said Nathalie Landry, VP Product of Medicago. "We are the first novel vaccine manufacturing technology to report an immune response of this kind at such low dosage levels. This is especially important as H5N1 vaccines are known to be poorly immunogenic in humans. The results indicate that we have a solid vaccine manufacturing platform and we look forward to continuing the clinical advancement of our vaccine candidates."